

TUESDAY, MAY 26		
8:00 am - 8:00 pm	Foundation Mentorship Program (by invitation only) E222	
12:00 pm - 2:00 pm	<p>An Update on Multiple Sclerosis Patient Care for Advanced Practice Providers E219A</p> <p>Lunch Symposium</p> <p><i>This activity is provided by AcademicCME. This CME/CE program is supported by independent educational grants from Sandoz, Sanofi, and TG Therapeutics, Inc.</i></p>	
2:00 pm - 6:30 pm	<p>An Update on Multiple Sclerosis Patient Care for Advanced Practice Providers E219A</p> <p>The 11th Annual Advanced Curriculum for Multiple Sclerosis Course</p> <p><i>This activity is provided by the CMSC and AcademicCME. This CME/CE program is supported by an independent educational grant from Genentech, Inc.</i></p>	
1:00 pm - 5:00 pm	CMSC Registration C CONCOURSE	
2:30 pm - 5:30 pm	<p>Forum for Clinical Trialists: Workshop on Best Practices E216 ABCD</p> <p><i>This independent education program is not included in the CMSC Annual Meeting accredited program. No CE credit provided.</i></p>	
3:00 pm - 6:00 pm	<p>Kinesio Taping for Neurological Conditions E212 ABCD</p> <p><i>This session does not offer continuing education credit.</i></p>	Lori Robinson, OTR/L, CKTI Amy Cassidy, PT
3:00 pm - 6:00 pm	<p>Botulinum Toxin Injections for Migraine and Spasticity in Multiple Sclerosis: A Hands-On Training Symposium E217</p> <p>IPCE CME AAPA ANCC</p>	Carolina Ionete, MD, PhD Chair
» 3:00 pm	» Introduction	Carolina Ionete, MD, PhD
» 3:05 pm	» Key Mechanisms of Spasticity in MS	Carolina Ionete, MD, PhD
» 3:20 pm	» Treatment Algorithms to Assist with Selection of Modalities	Agnes Bacopulos, MD
» 3:40 pm	» Botulinum Toxin (BoNT) Mechanism of Action and Indications for Treatment in Neurological Disorders	Molly Wilner, DO
» 4:00 pm	» Evaluating Spasticity and Choosing Muscle to Treat in the Upper Extremity and Lower Extremity (FDA Approved Muscles)	Idanis Berrios-Morales, MD
» 4:20 pm	» Q&A	Panel
» 4:30 pm	» Break	
» 4:45 pm	» Hands-on Session	Panel
6:00 pm - 7:30 pm	IOMSN Board Meeting W205ABCD	
6:15 pm - 9:30 pm	<p>The Red Carpet World Premiere of 'Because I Can' E219D</p> <p><i>This night would not be possible without the support of those who believe in this mission of the movement this film has become. Special thanks go to Genentech, our World Premiere & National Tour Sponsor, and to Biogen our World Premiere Presenting Sponsor.</i></p>	Allié McGuire
» 6:15 pm	» Red Carpet Arrival & Reception Walk the carpet, enjoy drinks and dinner	
» 7:00 pm	» Welcome Remarks	
» 7:15 pm	» World Premiere Screening	
» 8:30 pm	» Conversation with the Filmmakers & Guests	
» 9:00 pm	» Closing Reception & Live Performance	

WEDNESDAY, MAY 27		
7:00 am - 6:30 pm	CMSC Registration C CONCOURSE	
7:15 am - 7:50 am	Nursing in Rare Disease: Approach to Myasthenia Gravis and MOGAD E219BC <i>This session does not offer continuing education credit.</i>	Amy Perrin Ross, APN, MSN, CNRN, MSCN
8:00 am - 9:00 am	INDEPENDENTLY SUPPORTED SYMPOSIUM 1 Shaping Tomorrow Together: Incorporating the Patient Voice into MS Clinical Care and Treatment Innovation E220CD <i>This activity is provided by the CMSC and the National Multiple Sclerosis Society</i>	Nicole M. Boschi, PhD Hollie Schmidt, VP Daniel Ontaneda, MD, PhD
» 8:00 am	» Welcome and Opening Remarks	Karen Mariner, MSS Kathleen Costello, MS, CRNP, MSCN
» 8:05 am	» Introduction and Overview of Externally-Led Patient Focused Drug Development and Shaping Tomorrow Together	Nicole M. Boschi, PhD
» 8:15 am	» Highlights from Shaping Tomorrow Together Survey	Hollie Schmidt, VP
» 8:25 am	» Clinical Implications and Reflection: Moderated Discussion on Shaping Tomorrow Together	Daniel Ontaneda, MD, PhD Julie Fiol, RN, LMSW, MSCN
» 8:45 am	» Audience Q&A	Panel
» 8:55 am	» Closing Remarks	Karen Mariner, MSS
9:15 am - 9:45 am	Welcome and Membership Update: The New CMSC and You RICHARDSON BALLROOM	Kathleen Costello, MS, CRNP, MSCN
9:45 am - 10:45 am	THE JUNE HALPER MEMORIAL LECTURE The Journey is the Destination: 40 Years of CMSC, 40 Years of MS Neuropsychiatry RICHARDSON BALLROOM IPCE CME ACPPE ANCC AOTA NCPT AAPA APA RD ASWB	Anthony Feinstein, MPhil, PhD, FRCP
	Peer Exchange Sessions	
11:00 am - 12:00 pm	» Physicians E219A	
11:00 am - 12:00 pm	» Pharmacists / PharMS E219BC	
11:00 am - 12:00 pm	» Nurses and NPs / IOMSN E222	
11:00 am - 12:00 pm	» PAs / MS-PA E219D	
11:00 am - 12:00 pm	» Rehabilitation Professionals / IOMSRT E220AB	
11:00 am - 12:00 pm	» Mental Health Professionals / MS MHP E220CD	
11:00 am - 12:00 pm	» Registered Dietitians / MS-RD E221AB	
11:00 am - 12:00 pm	» MS Professionals in Training (MS-PIT) E217	
11:00 am - 12:00 pm	» Diversity, Equity and Inclusion (DEI) E216ABCD	
11:00 am - 12:00 pm	» MS Research Coordinator Network (MSCRN) E212ABCD	
12:00 pm - 2:30 pm	Exhibit Hall Open EXHIBIT HALL B	
12:15 pm - 1:15 pm	SUPPORTER SHOWCASE 1 - NOVARTIS PHARMACEUTICALS Clinical Data and Patient Perspectives: What Informs Treatment Decisions EXHIBIT HALL B	Dr. Mitzi Joi Williams Jamie Lynn Sigler, patient on RMS treatment

1:30 pm - 2:30 pm	<p>SUPPORTER SHOWCASE 2 - GENENTECH</p> <p>Illuminating the Dual Drivers of Progression Inside and Outside the CNS: Candid Conversations in Contemporary MS Evaluating Clinical Cases Through the Evolving Science of MS</p> <p>EXHIBIT HALL B</p>	<p>Lisa Fox, PA-C, MPAS Carrie M. Hersh, DO, MSc, FAAN Stephen Krieger, MD, FAAN Augusto Miravalle, MD, FAAN Scott D. Newsome, DO, MSCS, FAAN, FANA Jiwon Oh, MD, PhD, FRCPC, FAAN</p>
CLINICAL COURSES		
2:45 pm - 4:45 pm	<p>(CC01) Turning the Tide on MS: Prodrome and Prevention E220AB</p> <p><i>Organized by the VA MS CoE</i> IPCE CME ANCC AAPA</p>	Mitchell Wallin, MD, MPH, Chair
» 2:45 pm	» Introduction and Update on the MS Prodrome	Mitchell Wallin, MD, MPH
» 3:20 pm	» RIS Diagnosis and Clinical Management	Suma Shah, MD
» 3:50 pm	» Cohort Studies, Biomarkers and Prevention	Dalia Rotstein, MD
» 4:20 pm	» Case Discussion	Panel
2:45 pm - 4:45 pm	<p>(CC02) Era of Too Many Choices; Starting and Switching E219BC</p> <p>IPCE CME ACPE ANCC AAPA</p>	Scott D. Newsome, DO, MSCS, FAAN, FANA, Chair
» 2:45 pm	» Welcome and Introduction	Scott D. Newsome, DO, MSCS, FAAN, FANA
» 2:50 pm	» Treatment Approaches and Considerations in MS	Scott D. Newsome, DO, MSCS, FAAN, FANA
» 3:10 pm	» Decision Making Process Around What DMT to Start	Gabrielle Macaron, MD
» 3:40 pm	» Decision Making Process Around Switching DMTs in MS	Jiwon Oh, MD, PhD, FRCPC
» 4:10 pm	» Panel Roundtable-Case Presentations	Panel
» 4:40 pm	» Q & A	Panel
2:45 pm - 4:45 pm	<p>(CC03) Great Debate in MS Nursing: Are Digital Tools Enhancing or Eroding Patient Relationships? E221AB IPCE CME ANCC AAPA</p>	Bonnie Blain, RN, CNN(C), MSCN, Chair
» 2:45 pm	» The Digital Dilemma: Setting the Stage for a Great Debate	Bonnie Blain, RN, CNN(C), MSCN
» 3:00 pm	» Digital Tools Are Enhancing MS Care: Why Innovation Strengthens the Nurse–Patient Partnership » Focus: Pro argument	Sara Schaefer, NP-BC, CNRN, MSCN
» 3:20 pm	» Digital Tools Are Eroding MS Care: Why Human Connection Still Matters Most » Focus: Con argument	Jill Nelson, RN, BScN, MSCN
» 3:40 pm	» Point–Counterpoint: Where Do We Draw the Line?	Bonnie Blain, RN, CNN(C), MSCN
» 3:55 pm	» Vote	
» 4:10 pm	» Practical Strategies for Blending Digital and Human-Centered MS Care	Panel
» 4:30 pm	» Q & A–Your Verdict: Help Shape the Future of Digital MS Care	
2:45 pm - 4:45 pm	<p>(CC04) Integrating Wearables into MS Clinical Care: From Research to Routine Practice E219D IPCE CME ANCC AOA NCPT AAPA APA ASWB</p>	Valerie Block, PT, DPTSc, Chair
» 2:45 pm	» Sleep Tracking in MS: Research Insights, Clinical Implications	Tiffany J. Braley, MD, MS
» 3:20 pm	» Counting Steps, Capturing Bladder: Clinically Useful Wearables in MS	Valerie Block, PT, DPTSc
» 3:55 pm	» Actionable Data at the Point of Care: Best Practices	Riley Bove, MD, MS
» 4:35 pm	» Q & A	Panel

2:45 pm - 4:45pm 	(CC05) GLP-1-RA Meets MS: Why, How, What's Next E219A          	Libby Levine, MSN, AGNP-BC, MSCN, Chair
» 2:45 pm	» From Discovery to Therapy: The Evolution of GLP-1 Receptor Agonists	Donald Langan, MD, PharmD
» 3:20 pm	» GLP-1 Receptor Agonists in Multiple Sclerosis: Mechanistic Rationale, Ongoing Research, and Prospective Applications	Lisa Fox, PA-C
» 3:55 pm	» The GLP-1 Receptor Agonist Era in MS Care: How to Support Your Patients	Libby Levine, MSN, AGNP-BC, MSCN
» 4:30 pm	» Q & A	Panel
2:45 pm - 4:45pm 	(CC06) Managing Non-Multiple Sclerosis Patients in a Multiple Sclerosis Practice: Rare Neuroimmunological Disorders – Everything You Need to Know Part 1 E216ABCD          	Benjamin Greenberg, MD, Chair
» 2:45 pm	» Introduction to Rare Neuroimmune Disorders	Benjamin Greenberg, MD
» 3:45 pm	» 2025 Updates to Diagnostic Criteria and Nosology for Myelitis	Kyle Blackburn, MD
2:45 pm - 4:45 pm 	(CC07) Spinal Cord in MS: Key Clinical and Imaging Considerations E217     	B. Mark Keegan, MD, Chair
» 2:45 pm	» Clinical Importance of MS Spinal Cord Demyelination	Anne Kerbrat, MD, PhD
» 3:10 pm	» "Critical" Decision-making in Assessing the Spinal Cord in MS	B. Mark Keegan, MD
» 3:35 pm	» Spinal Cord MRI in MS- Why, When and How Often?	Jiwon Oh, MD, PhD, FRCPC
» 4:00 pm	» Traditional and Novel MS Spinal Cord Imaging- Which Measures Actually Measure Up?	Roland Henry, PhD
» 4:25 pm	» Q & A	Panel
2:45 pm - 4:45pm	(CC08) Making the Invisible Visible E220CD          	Alexandra Simpson, MD, MA, Chair
» 2:45 pm	» Introduction/Invisible Symptoms in MS	Alexandra Simpson, MD, MA
» 3:00 pm	» Fatigue and Sleep in MS: "But You Look So Good!"	Mini Singh, MD
» 3:30 pm	» Out of Sight, But Not Out of Mind	Robert Shin, MD
» 4:00 pm	» Integrating Invisible Symptoms into MS Care and Research	Alexandra Simpson, MD, MA
» 4:25 pm	» Q & A	Panel
2:45 pm - 4:45pm	(CC09) Cognitive Screenings for Multiple Sclerosis: What Should Clinicians Know and How Can We Improve Access to Care? E212ABCD       	Elizabeth S. Gromisch, PhD, MSCS, Chair
» 2:45 pm	» Introduction	Elizabeth S. Gromisch, PhD, MSCS
» 2:50 pm	» The Importance of Routine Cognitive Screenings for Comprehensive MS Care	John DeLuca, PhD, ABPP
» 3:15 pm	» Implementing Screenings in the Clinic: Validated Tools and Best Clinical Practices	Elizabeth S. Gromisch, PhD, MSCS
» 3:45 pm	» Beyond Cognition: Screening for Mood and Other Symptoms	Frederick W. Foley, PhD
» 4:00 pm	» Developing New Solutions for Cognitive Screenings: A Patient's Perspectives	Samari Souss, MA
» 4:20 pm	» Addressing Barriers in Clinical Practice: Panel Discussion and Q&A	Panel

2:45 pm - 4:45pm	(CC10) OCT Across the Spectrum of Demyelinating Disease E222	Scott N. Grossman, MD, Chair
	IPCE CME ANCC AAPA	
» 2:45 pm	» Historical and Technical Perspective on OCT in MS	Scott N. Grossman, MD
» 3:20 pm	» OCT in the 2024 McDonald Criteria	Rachel Kenney, PhD
» 3:40 pm	» Artificial Intelligence and OCT in Demyelinating Disease	Rachel Kenney, PhD
» 4:00 pm	» OCT in MOGAD and NMOSD	Clotilde Hainline, MD
» 4:35 pm	» Q & A	Panel
4:30 pm - 6:00 pm	INDEPENDENTLY SUPPORTED SYMPOSIUM 2 New Pathways, New Possibilities in Multiple Sclerosis: BTK Inhibition and the Future of Patient Care RICHARDSON BALLROOM <i>This CME/MOC/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.</i> <i>This activity is supported by an educational grant from Genentech, a member of the Roche Group.</i>	Jiwon Oh, MD, PhD, FRCPC Gregory F. Wu, MD, PhD, FAAN
» 4:30 pm	» Registration & Hors d'Oeuvres	
» 5:00 pm	» Welcome and Introduction	Jiwon Oh, MD, PhD, FRCPC
» 5:05 pm	» The Rise of BTK Inhibitors in MS	Gregory F. Wu, MD, PhD, FAAN
	» TownHall Sessions	
» 5:15 pm	▶ Identifying the Right Fit for BTK Inhibition	Jiwon Oh, MD, PhD, FRCPC
» 5:35 pm	▶ Monitoring MS to Guide Better Outcomes	Gregory F. Wu, MD, PhD, FAAN
» 5:55 pm	» Closing Remarks and Final Q&A Session	Jiwon Oh, MD, PhD, FRCPC Gregory F. Wu, MD, PhD, FAAN
6:00 pm - 7:30 pm	Exhibit Hall Open EXHIBIT HALL B	
6:15 pm - 7:15 pm	SUPPORTER SHOWCASE 3 - UCB, INC Targeting FcRn in Generalized Myasthenia Gravis with RYSTIGGO® (rozanolixizumab-noli) EXHIBIT HALL B	Amy Perrin Ross, APN, MSN, CNRN, MSCN
6:45 pm - 7:45 pm	IOMSN Reception E222	
8:00 pm - 10:00 pm	First Night (NASCAR Hall of Fame) NASCAR HALL OF FAME <i>Supported by Bristol Myers Squibb</i>	

THURSDAY, MAY 28

7:00 am - 8:00 am	<p>INDEPENDENTLY SUPPORTED SYMPOSIUM 3</p> <p>What Would You Do?</p> <p>Clinical Case Challenges for Optimal MS Care RICHARDSON BALLROOM</p> <p><i>This activity is provided by the CMSC and Catamount Medical Education, LLC. This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.</i></p>	Robert J. Fox, MD, FAAN Scott D. Newsome, DO, MSCS, FAAN, FANA
	» Introductory Remarks and Explanation of the Program Format	
	» Case Challenges: <ul style="list-style-type: none"> ▶ A Patient Being Evaluated Using the Latest Diagnostic Criteria ▶ A Newly Diagnosed MS Patient with Highly Active Disease ▶ A Patient with Relapsing MS Showing Disability Progressions Independent of Relapse Activity 	
	» Questions and Answers	
7:30 am - 5:30 pm	CMSC Registration C CONCOURSE	
SYMPOSIA		
8:15 am - 11:15 am	<p>(SYM01) Fundamentals of MS Care Part 1: The History of MS, Diagnosis, Managing Specific Population, and Comprehensive Care</p> <p>E220AB IPCE CME ACPE ANCC AAPA</p>	Patricia Pagnotta, APRN, Moderator
» 8:15 am	» Introduction	Patricia Pagnotta, APRN
» 8:20 am	» The Natural History of MS (Epidemiology, Immunology, Pathophysiology)	Bruce Cohen, MD
» 9:00 am	» Making the Diagnosis (Disease Mimics, Use of Paraclinical Tools)	John Ciotti, MD
» 9:40 am	» Break	
» 9:55 am	» MRI Mimics in the Diagnosis of MS	David K.B. Li, MD, FRCPC
» 10:35 am	» Use and Effectiveness of Marijuana in MS: Research Update	Anthony Feinstein, MPhil, PhD, FRCP
8:15 am - 11:15 am	<p>(SYM02) Current Topics and Trends in Rehabilitation Part 1</p> <p>Multiple Sclerosis Rehabilitation in Focus: Evidence-based Interventions to Improve Mobility Deficits</p> <p>E221AB IPCE CME ANCC AOTA NCPT AAPA APA ASWB</p>	Patty Bobryk, MHS, PT, MSCS, ATP, Moderator Herb Karpatkin, PT, DSc, GCS, NCS, MSCS, Chair
» 8:15 am	» Introductions and Opening Remarks	Evan T. Cohen, PT, MA, PhD, NCS
» 8:25 am	» Current Understanding of MS Pathophysiology and Medical Management	Evan T. Cohen, PT, MA, PhD, NCS
» 8:50 am	» The State of the Evidence for Mobility Rehabilitation for People with MS	Evan T. Cohen, PT, MA, PhD, NCS, Herb Karpatkin, PT, DSc, GCS, NCS, MSCS
» 9:45 am	» Break	
» 10:00 am	» Model of Care Integration	Gregory A. Brusola, PT, DPT, PhD, MSCS
» 10:35 am	» Addressing the Unmet Needs of our Patients with MS	Gregory A. Brusola, PT, DPT, PhD, MSCS
» 11:00 am	» Conclusions and Q&A	Panel

8:15 am - 11:15 am	(SYM03) International Symposium on Gait & Balance in MS: Strength in Motion: Exercise and Safety for Wheelchair Users with MS E220CD IPCE CME ANCC AOTA NCPT AAPA APA ASWB	Nora Fritz, PhD, DPT, NCS, Chair Kathleen M. Zackowski, PhD, OTR, Co-Chair
» 8:15 am	» Falls in Non-ambulatory Individuals with Multiple Sclerosis	Jacob Sosnof, PhD
» 9:00 am	» Promoting Valued Participation and Activity through Fall Prevention and Management Among People Living with MS who use Wheelchairs and Scooters	Laura Rice, PhD, MPT, ATP
» 9:45 am	» Break	
» 10:00 am	» Building Exercise Solutions With, Not For, Wheelchair Users With MS: A Community-Engaged Journey to Program Development and Outcome Selection	Stephanie Silveira, PhD
» 10:45 am	» Q&A	Panel
8:15 am - 11:15 am	(SYM04) Treating MS in 2025: Practical Issues and Special Considerations E212ABCD IPCE CME ACPE ANCC AOTA AAPA APA ASWB <i>Organized by the VA MSCoE</i>	Francesca Bagnato, MD, PhD, Chair
» 8:15 am	» Introduction	Francesca Bagnato, MD, PhD
» 8:20 am	» Treating Neuroimmunological Conditions during Pregnancy and Breastfeeding	Suma Shah, MD
» 8:45 am	» Treating Neuroimmunological Condition in the Elderly	Francesca Bagnato, MD, PhD
» 9:10 am	» Vaccines in Patients with Neuroimmunological Conditions	Patti Yager-Stone, PharmD, BCPS
» 9:35 am	» Break	
» 9:50 am	» Treating Neuroimmunological Conditions in Patients with other Autoimmune Conditions	Francesca Bagnato, MD, PhD
» 10:20 am	» Treating Neuroimmunological Conditions at the Time of Surgery	Suma Shah, MD
» 10:45 am	» Special Nursing and Logistical Consideration for Veterans with MS	Melinda Hungerford, RN
» 11:10 am	» Conclusive Remarks	
8:15 am - 11:15 am	(SYM05) MS Update 2026 E219D IPCE CME ACPE ANCC AAPA APA ASWB	Patricia K. Coyle, MD, Chair
» 8:15 am	» A Primer on Biomarkers	Patricia K. Coyle, MD
» 8:55 am	» MS Misdiagnosis and Mimickers	Patricia Melville, RN, MSN, NP-BC, MSCN
» 9:35 am	» Break	
» 9:50 am	» Update on Cognitive Impairment in MS and Potential Interventions	Marjean Buhse, PhD, RN, ANP-BC, MSCN, FAAN
» 10:30 am	» Mood Disorders in MS	Patricia Melville, RN, MSN, NP-BC, MSCN
» 11:10 am	» Discussion/Q&A	Panel
8:15 am - 11:15 am	(SYM06) Psychosocial Well-Being Across the MS Lifespan: From Adolescence to Older Adulthood E219A IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	
» 8:15 am	» Part 1: The Psychosocial Impact of MS in Adolescents: Providing Supportive Care	Joley Johnstone, RN, MN, NP, Chair Iris Garcia, MSW, HBSW, HBA, RSW
» 9:30 am	» Break	
	» Part 2: Mental Health and Aging with MS: Every Provider Plays a Role	Terry Lee-Wilk, PhD, Chair

» 9:45 am	▶ Introductions	Jessica Dalrymple, PhD Moirá Dux, PhD Terry Lee-Wilk, PhD
» 9:50 am	▶ Mental Health Considerations with Aging and MS Progression ▶ Mental Health is Every Discipline's Responsibility: Practical Strategies for Providers	Panel
» 10:30 am	▶ Overview of Evidence Based Interventions and Mental Health Resources ▶ Key Takeaways and Conclusions	Panel
8:15 am - 11:15 am	(SYM07) Bugs and Drugs: Practical Management Considerations Around Infections and MS Disease Modifying Therapies E219BC IPCE CME ACPE ANCC AAPA	Robert J. Fox, MD, FAAN, Chair
» 8:15 am	» Introduction	Robert J. Fox, MD, FAAN
» 8:20 am	» Infections with Steroids, ABCR, Fumarates, Natalizumab	Hilary Young, PA-C
» 8:50 am	» Infections with S1Ps, B Cell Depleters, Alectuzumab, and Mavenclad	Grace Wortland, AGP-C, MSN, MSCN
» 9:20 am	» Break	
» 9:35 am	» Infection Management Strategies: General, S1Ps, B Cell Depleters, Mavenclad	Enrique Alvarez, MD, PhD
» 10:10 am	» Infection Management Strategies: Fumarates, Natalizumab, Alectuzumab	Robert J. Fox, MD, FAAN
» 10:45 am	» Cases and Audience Discussion	Panel
8:15 am - 11:15 am	(SYM08) Emerging Cell-based Therapies in Multiple Sclerosis E217 REC IPCE CME ACPE ANCC AAPA	Mark Freedman, MSc, MD, FRCPC, Chair
» 8:15 am	» aHSCT Update	Mark Freedman, MSc, MD, FRCPC
» 8:55 am	» Neural Stem Cells for the Treatment of MS	Gianvito Martino, MD
» 9:35 am	» Break	
» 9:45 am	» CAR-T as a Potential Treatment	Jeffrey A. Cohen, MD
» 10:25 am	» Cell Replacement Therapy for MS	Jaime Imitola, MD
» 11:05 am	» Wrap-up and Q&A	Panel
8:15 am - 11:15 am	(SYM09) Responding to the Needs of Individuals with Advanced MS: Integrated Approaches to Care, Function, and Quality of Life E216ABCD REC IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Rachael Stacom, ANP-BC, MSN, MSCN, Chair
» 8:15 am	» Introduction: Framing Advanced MS	Rachael Stacom, ANP-BC, RN, MSCN
» 8:30 am	» Medical Management: Preserving Function & Reducing Symptoms	Stephen Krieger, MD
» 9:00 am	» Assistive Technology to Maximize Function, Mobility and Health in Advanced MS	Elaine Castelluccio, PT, MPT, MSCS, CDP
» 9:30 am	» Break	
» 9:45 am	» Protecting Health in Advanced MS: Preventing and Treating the Most Common Complications	Renee Stewart, APRN-NP, DNP
» 10:15 am	» The Power of Peer Connections & Caregiver Support: Improving Outcomes and Sustaining Joy	Rachael Stacom, ANP-BC, RN, MSCN
» 10:45 am	» Clinical Cases for Discussion	Panel

11:30 am - 12:15 pm	<p>DONALD PATY LECTURE</p> <p>Adventures at the Poles: Ultra-Low and Ultra-High-Field MRI for MS</p> <p>RICHARDSON BALLROOM      </p>	Daniel S. Reich, MD, PhD
11:30 am - 2:45 pm	<p>Exhibit Hall Open </p>	
12:30 pm - 2:30 pm	<p>Foundation Scholar Luncheon </p>	
12:30 pm - 1:30 pm	<p>SUPPORTER SHOWCASE 4 - OCTAVE BIOSCIENCE</p> <p>Quantifying MS Disease Activity: Integrating Serum Biomarkers into MS Care </p>	Darin T. Okuda, MD. Leorah Freeman, MD, PhD Matthew C. Carraro, MD
1:00 pm - 2:30 pm	<p>Veterans Affairs MS Centers of Excellence Business Meeting (open to all VA) </p>	
1:45 pm - 2:45 pm	<p>Managing Progression in Multiple Sclerosis: A Consensus Statement on Best Practices </p> <p>Update from the CMSC</p> <p><i>This project is supported by an independent grant from Sanofi.</i></p>	Sarah D. Morrow, MD, FRCP(C) Benjamin Greenberg, MD
3:00 pm - 5:00 pm	<p>Disease Modifying Therapies Platform Session </p> <p>    </p>	
» 3:00 pm	<p>» (DMT01) Efficacy and Safety of Frexalimab In Participants with Relapsing Multiple Sclerosis: 3-Year Results from the Phase 2 Open-Label Extension</p>	Stephen Krieger, MD
» 3:20 pm	<p>» (DMT02) Real-World Effectiveness and Safety of Cladribine Tablets In Older Patients with Relapsing Multiple Sclerosis: Insights from the 'aging' Study Subgroup Analysis</p>	Amy Gutierrez, MD
» 3:40 pm	<p>» (DMT03) Ubituximab Significantly Improves Patient-Reported Outcomes: Results from the Phase 4 Observational Study ENABLE</p>	Carrie M. Hersh, DO, MSc, FAAN
» 4:00 pm	<p>» (DMT04) Real-World Effectiveness and Safety of Ozanimod for Relapsing-Remitting Multiple Sclerosis In the Prospective Noninterventional OzEAN Study In Germany: 3-Year Results</p>	Mathias Buttman, MD
» 4:20 pm	<p>» (DMT05) A Decade of Pregnancy Outcomes in Women with Multiple Sclerosis Receiving Ocrelizumab: Analysis of Over 5000 Pregnancies</p>	Kristen M. Krysko, MD
» 4:40 pm	<p>» (DMT06) Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study</p>	Jacqueline A. Nicholas, MD, MPH
3:00 pm - 4:15 pm	<p>Epidemiology and Disease Management Platform Session </p> <p>         </p>	
» 3:00 pm	<p>» (EP101) Understanding Real-World Engagement with a Patient Monitoring App: Insights from the Remote Multiple Sclerosis Care In Antwerp (ReMSCA) Study</p>	Judith Derdelinckx, MD, PhD
» 3:25 pm	<p>» (EP102) Distinct Demographic and Inflammatory Modifiers of Treatment Non-Response across Multiple Sclerosis Therapies</p>	Robert C. Axtell, PhD
» 3:50 pm	<p>» (EP103) Dietary Associations with Biological Aging Markers In Pediatric-Onset Multiple Sclerosis</p>	Maria A. Piedrabuena, MD
» 4:15 pm	<p>» (EP104) Educating Patients with Multiple Sclerosis on Health and Wellness Strategies through Shared Medical Appointments: A Quality Improvement Initiative</p>	Erin Wilkinson, DNP, APRN, FNP-BC, MSCN

3:00 pm - 5:00 pm	Rehabilitation Platform Session E219BC 	
» 3:00 pm	» (REH01) Preliminary Efficacy of a Wheelchair Exercise Training Program for Persons with Multiple Sclerosis	Stephanie Silveira, PhD
» 3:20 pm	» (REH02) Awareness and Knowledge of MS-Specific Exercise Guidelines Among the US MS Population	Louise Declerck, PhD
» 3:40 pm	» (REH03) Translating Innovation into Impact: Improving Access and Precision In MS Care By Integrating Tailored Remote Monitoring with AI-Enabled Decision Support	Brad Willingham, PhD
» 4:00 pm	» (REH04) Computer-Based Cognitive Rehabilitation Improves Satisfaction with Cognitive Performance In Multiple Sclerosis: A Non-Blinded Randomised Controlled Trial	Keelia Quinn de Launay, MSc, MScOT
» 4:20 pm	» (REH05) Randomized Controlled Trial of a Remotely-Delivered Exercise Training Program In Older Adults with Multiple Sclerosis: Secondary Effects on Cognition, Symptoms, and Quality of Life	Peixuan Zheng, PhD
» 4:40 pm	» (REH06) Cognitive Telerehabilitation for People with MS. Results from the Remote-MS Study	Andrea Tacchino, PhD
3:00 pm - 5:00 pm	Imaging and Biomarkers Platform Session E221AB 	
» 3:00 pm	» (IMG02) Early Diffusion Tensor Abnormalities and Myelin Water Imaging In Radiologically Isolated Syndrome	Elena Kovacevic, BASc Candidate
» 3:30 pm	» (IMG03) Relationship between Baseline and Longitudinal Neurofilament Light Chain Levels and Cognition In Relapsing Multiple Sclerosis: 3-Year Phase 3B ENLIGHTEN Study Results	John DeLuca, PhD
» 4:00 pm	» (IMG04) Utilizing the NARCRMS Database to Identify Associations between Sociodemographic Factors and Disability In Multiple Sclerosis	Brinda Bhaskar, MD
» 4:30 pm	» (IMG05) Improvements In Ultra-Low Field Portable MRI and Applications for Multiple Sclerosis	Anthony Trabulsee, MD
3:00 pm - 5:00 pm	Cognitive Function, Psychosocial, and Quality of Life Metrics Platform Session E212ABCD 	
» 3:00 pm	» (PSY01) Cognitive Function In Multiple Sclerosis Is Qualitatively Different within the Modern Diagnostic and Treatment Era: Memory Difficulty Despite Normal Cognitive Speed	James F. Sumowski, PhD
» 3:20 pm	» (PSY02) Association of Racial Identity, Neighborhood Marginalization, and Levels of Depression, Fatigue, and Anxiety In Pediatric Patients with Acquired Demyelinating Disorders	Sophie L. Wagner, BHSc
» 3:40 pm	» (PSY03) Looking Beyond Dose: Identifying Responders and Non-Responders to Rehacom Computerized Cognitive Rehabilitation In Progressive MS—the CogEx Study	Cecilia Meza, MA
» 4:00 pm	» (PSY04) Access, Relationships, and Community (ARC) to DisruptMS: A Scalable Recruitment Framework for Black Persons Living with Multiple Sclerosis	Evelyn A. Hunter, PhD
» 4:20 pm	» (PSY05) Impact of Scalable 1-1 Peer Support on Increasing Confidence In Self-Management and Decision-Making: A Five-Year Evaluation of the Shift. Ms Buddy Network	Victoria Kirk
» 4:40 pm	» (PSY06) Validation of a Survey Assessing Perceptions and Barriers to Research Participation Among Minority Patients with Multiple Sclerosis	Michael V. Robers, MD, MS

Program (Thursday)



2026
ANNUAL
MEETING

3:00 pm - 5:00 pm	(CC11) Driving Discovery in MS: The Power of Research Integrated Care E220AB IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Dawn Carle, RN, BScN, Chair
» 3:00 pm	» Welcome and Overview: Research as the Foundation of MS Progress	Dawn Carle, RN, BScN
» 3:10 pm	» From Bench to Bedside: How Clinical Research Shapes the Future of MS Treatment	Mark S. Freedman, HBSc MSc, MD, CSPQ, FANA, FAAN, FRCPC
» 3:50 pm	» The Research Coordinator & Clinic Perspective: Navigating Trials, Teams, and Patient Partnerships	Tammy Pham, BSc, MSc, MPAS
» 4:30 pm	» Integrating Research and Clinical Practice: Building Sustainable MS Research Programs	Dawn Carle, RN, BScN
» 4:55 pm	» Q & A and Closing Remarks	Panel
3:00 pm - 5:00 pm	(CC12) Malnutrition, Body Composition, and Frailty in MS E216ABCD IPCE CME ANCC AOTA NCPT AAPA APA RD ASWB	Tyler J. Titcomb, PhD, RDN, Chair
» 3:00 pm	» Welcome and Introduction	Tyler J. Titcomb, PhD, RDN
» 3:10 pm	» Malnutrition – A Potentially Underappreciated Concern in MS	Tyler J. Titcomb, PhD, RDN
» 3:40 pm	» Beyond BMI: Body Composition Outcomes and Management in MS	Ariel Kidwell-Chandler, MA
» 4:10 pm	» Understanding and Managing Frailty in People with MS	Tobia Zanotto, PhD
» 4:40 pm	» Q & A	Panel
3:00 pm - 5:00 pm	(CC13) Disco and Beyond Disco with a Pharmacists' Twist E217 IPCE CME ACPE ANCC AAPA	Jacquelyn Bainbridge, PharmD, FCCP, Chair
» 3:00 pm	» Introduction	Jacquelyn Bainbridge, PharmD, FCCP
» 3:10 pm	» Disease Modifying Therapy Discontinuation in MS: DISCOMS and other Controlled Trials	John Corbooy, MD
» 3:40 pm	» Beyond Disco	Andrew Wolf, MD
» 4:20 pm	» The Pharmacist Twist	Sharon (Ross) Tingen, PharmD
3:00 pm - 5:00 pm	(CC14) Community Wellness Program Models for People Living with MS E219A IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Brian Hutchinson, PT, MSCS, Chair
» 3:00 pm	» Introduction to Community Wellness Programs	Brian Hutchinson, PT, MSCS
» 3:15 pm	» John A. Schafer, MD Multiple Sclerosis Achievement Center: A Day Wellness Program Model	Tiffany Malone, MSW, MSCS
» 3:45 pm	» My Strength Wellness Program	Lynsey Lakin, DNP, FNP-C
» 4:15 pm	» The Can Do Approach to a Healthy Lifestyle	Rosalind Kalb, PhD, CHC
» 4:45 pm	» Q & A	
4:30 pm - 7:00 pm	Exhibit Hall Open EXHIBIT HALL B	
5:00 pm - 7:00 pm	Poster Session (authors stand by their work 6-7) EXHIBIT HALL B	
5:00 pm - 6:00 pm	IOMSN Industry Council Mixer EXHIBIT HALL B	
7:00 pm - 9:00 pm	Giants of Multiple Sclerosis Awards RICHARDSON BALLROOM	

FRIDAY, MAY 29		
6:00 am - 7:00 am	Foundation Yoga RICHARDSON PREFUNCTION/TERRACE	
7:00 am - 8:00 am	Late-Breaking Abstracts E216ABCD	
» 7:00 am	» Efficacy and Safety of Fenebrutinib Vs Teriflunomide In Relapsing Multiple Sclerosis: Results of the Enhance 1 and 2 Studies	Jacqueline A. Nicholas, MD, MPH
» 7:20 am	» Effects of Established Immune-Mediated Disease Risk Factors on the Risk of AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Two-Sample Mendelian Randomization Study	Nahad Sedaghat, MD
» 7:40 am	» Efficacy and Safety of Ofatumumab Versus Teriflunomide In Participants with Highly Active Relapsing Multiple Sclerosis: Subgroup Analysis from Asclepius I/II	Patricia Coyle, MD
7:30 am - 4:00 pm	CMSC Registration C CONCOURSE	
8:15 am - 9:00 am 	JOHN WHITAKER LECTURE The Illusion of Equivalence? Generic and Biosimilar Disease-Modifying Therapies in Multiple Sclerosis RICHARDSON BALLROOM IPCE CME ACPE ANCC AAPA	Darin T. Okuda, MD, FAAN, FANA
9:00 am - 4:30 pm	Can Do Multiple Sclerosis <i>More About MS Patient Program</i> THE WESTIN	
9:15 am - 12:15 pm	(SYM10) Fundamentals of MS Care Part 2: The History of MS, Diagnosis, Managing Specific Population, and Comprehensive Care E220AB IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Patricia Pagnotta, APRN, Moderator
» 9:15 am	» Introduction	Patricia Pagnotta, APRN
» 9:20 am	» Primary Progressive MS: Diagnosis, Clinical Course, and Management	Patricia Coyle, MD
» 10:00 am	» Women's Issues in MS: Pregnancy, Sexual Function, and Menopause	Riley Bove, MD
» 10:40 am	» Break	
» 10:55 am	» Day to Day Management: The Role of a Triage Nurse	Charlotte Craig, RN
» 11:35 am	» The Spokes of Care: Can Comprehensive Care be Done Effectively without Walls	Christina Isbell, RN Patricia Pagnotta, APRN
9:15 am - 12:15 pm 	(SYM11) Current Topics and Trends in Rehabilitation Part 2 E217 IPCE CME ACPE ANCC AOTA NCPT AAPA APA ASWB	Patty Bobryk, MHS, PT, MSCS, ATP, Moderator
» 9:15 am	» Neuromodulation for Functional Recovery in MS: The Role of Spinal Cord Stimulation - Part A	Sarah Simmons, MD PhD, Chair
» 9:15 am	» Introduction to Neuromodulation as a Tool for Functional Recovery After Neurologic Injury	Sarah Simmons, MD PhD
» 9:30 am	» Non-invasive Spinal Cord Stimulation for Functional Recovery: Evidence Leading to FDA-approval in People Living with Traumatic Spinal Cord Injury	Fatma Inanici, MD, PhD
» 10:00 am	» Non-invasive Spinal Cord Stimulation for Functional Recovery of Hand and Arm Function in Multiple Sclerosis: Results from a Pilot Randomized Crossover Trial	Sarah Simmons, MD PhD
» 10:35 am	» Q & A	Panel
» 10:45 am	» Break	

» 11:00 am	» Fatigue and Fatigability in Multiple Sclerosis: Mechanisms, Measurement, and Management - Part B	Matthew Plow, PhD, Chair
» 11:00 am	▶ Overview	Matthew Plow, PhD, Chair
» 11:05 am	▶ Measuring Fatigue Constructs in MS	Anna Kratz, PhD
» 11:10 am	▶ The Role of Physical Activity and Activity Pacing in Fatigue Self-management	Matthew Plow, PhD, Chair
» 11:35 am	▶ Medication and Psychological Interventions for Fatigue management	Anna Kratz, PhD
» 12:00 pm	▶ Q&A	
9:15 am - 12:15 pm 	(SYM12) Managing Non-Multiple Sclerosis Patients in a Multiple Sclerosis Practice: Rare Neuroimmunological Disorders – Everything You Need to Know Part 2 E126ABCD IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Benjamin Greenberg, MD, Chair
» 9:15 am	» Introduction to Day 2 Agenda	Benjamin Greenberg, MD
» 9:30 am	» AQP4 NMOSD and MOGAD	Eoin Flanagan, MD
» 10:15 am	» Neurosarcoid	Carlos Pardo-Villamizar, MD
» 10:45 am	» Break	
» 11:00 am	» Stiff Person Syndrome	Scott D. Newsome, DO, MSCS, FAAN, FANA
» 11:30 am	» Disease Modifying Therapies for NMO, MOGAD, Sarcoid and SPS	Sean Pittcock, MD
9:15 am - 12:15 pm 	(SYM13) Emerging and Established Biomarkers in Neuroinflammatory Disease E221AB IPCE CME ANCC AAPA	Mark S. Freedman, HBSc MSc, MD, CSPQ, FANA, FAAN, FRCPC, Chair
» 9:15 am	» Introduction	Mark S. Freedman, HBSc MSc, MD, CSPQ, FANA, FAAN, FRCPC
» 9:30 am	» Roles of NFL and GFAP	Ahmed Abdelhak, MD
» 10:15 am	» Break	
» 10:30 am	» Biomarkers in NMO and MOGAD	Philippe Biloiseau, MD
» 11:15 am	» Multivariate MS Biomarkers Across Age Groups	Tanuja Chitnis, MD
» 12:00 pm	» Q & A	Panel
9:15 am - 12:15 pm 	(SYM14) McDonald Criteria Part 1 – Use of MRI and Other Biomarkers with the 2024 McDonald Criteria E219A IPCE CME ANCC AAPA	David K.B. Li, MD, FRCPC, Co-Chair Wallace Brownlee, MD, PhD, FRACP, Co-Chair
» 9:15 am	» Welcome and Introductions	David K.B. Li, MD, FRCPC Wallace Brownlee, MD, PhD, FRACP
» 9:20 am	» 2024 McDonald Criteria, Highlighting the Main Differences	Wallace Brownlee, MD, PhD, FRACP
» 9:45 am	» Standardized MRI Protocol, Revisions and Use	David K.B. Li, MD, FRCPC
» 10:15 am	» Break	
» 10:30 am	» Optic Nerve (MRI, OCT, VEP in People with and without Optic Neuritis)	Scott N. Grossman, MD
» 11:00 am	» Central Vein Sign (CVS) and Paramagnetic Rim Lesions (PRL)	Pascal Sati, PhD
» 11:30 am	» Fluid Biomarkers	Wallace Brownlee, MD, PhD, FRACP
» 11:45 am	» Case Discussion and Q&A	Panel

9:15 am - 12:15 pm	(SYM15) Whitaker Invited Lectures E212ABCD IPCE CME ACEP ANCC AOTA NCPT AAPA APA RD ASWB	Ahmed Obeidat, MD, PhD, Chair
» 9:15 am	» GLP-1 Agonists and Similar Treatments in Multiple Sclerosis	Farrah J. Mateen, MD, PhD
» 10:00 am	» Artificial Intelligence Applications in Multiple Sclerosis	Moein Amin, MD, MS
» 10:45 am	» Break	
» 11:00 am	» Changing the Rules: Reimagining Clinical Trials in Multiple Sclerosis	Ahmed Obeidat, MD, PhD
» 11:45 am	» Q & A	Panel
9:15 am - 12:15 pm	(SYM16) Beyond the Label: Navigating Biomarkers, Supplements, and High-Risk Patients E219BC IPCE CME ACEP ANCC AAPA	Jenelle H. Montgomery, PharmD, BCACP, CPP, Chair
» 9:15 am	» Introduction	Jenelle H. Montgomery, PharmD, BCACP, CPP
» 9:20 am	» Optimizing MS Clinical Management Through Biomarker Integration	Marion Thomas, MSN, APRN, FNP-C
» 10:00 am	» Management of High-risk MS Patients- Part I	Stephanie Iyer, PharmD, CPP, BCACP
» 10:40 am	» Break	
» 10:55 am	» Management of High-risk MS patients- Part II	Stephanie Iyer, PharmD, CPP, BCACP
» 11:35 am	» Supplements in Multiple Sclerosis	Julie Kidd, PharmD, MPH, BCPS
» 12:05 pm	» Q & A	Panel
9:15 am - 12:15 pm	(SYM17) Stronger You, Stronger MS Care E219D IPCE CME ACEP ANCC AOTA NCPT AAPA APA RD ASWB	Carrie M. Hersh, DO, MSc, FAAN, Chair
» 9:15 am	» Introductions	Panel
» 9:25 am	» Post-It Ice Breaker Session: Sharing Ideas and Knowledge Gaps	Panel
» 9:45 am	» Refilling the Cup: How Gratitude Sustains Caregivers	Amy Sullivan, PsyD, ABPP
» 10:15 am	» Holding onto the Why: Intention, Passion, and Joy in Meaningful Work	Carrie M. Hersh, DO, MSc, FAAN
» 10:45 am	» Break	
» 11:00 am	» Sustaining the Caregivers: Neuroscience-Driven Team Building in MS Care	Mary Rensel, MD
» 11:30 am	» Keeping it on the Rails: Recalibrating, Resetting, Resilience	Mary Alissa Willis, MD, FAAN, FANA
» 12:00 pm	» Networking/Speed Mentoring/Sharing Ideas	Panel
9:15 am - 12:15 pm	(SYM18) The Critical Role of Diet in MS Management: An Evidence-based Clinical Perspective E220CD IPCE CME ANCC AOTA AAPA APA ASWB	Laura Piccio, MD, PhD Chair
» 9:15 am	» Introduction	Laura Piccio, MD, PhD
» 9:20 am	» What Data Do We Have, and What is Coming Next: Scientific Foundation	Laura Piccio, MD, PhD
» 10:00 am	» Break	
» 10:15 am	» Value of the Dietician: Guidelines and Misconceptions	Diana Lehner-Gulotta RDN, CNSC
» 10:45 am	» Integrating Nutrition and Dietary Counseling into the Care of Persons with MS-Case Examples	J. Nicholas Brenton, MD Diana Lehner-Gulotta, RDN, CNSC
» 11:20 am	» The Role of Lifestyle Choices in Promoting Brain Health for People with MS	Barbara Giesser, MD
» 11:45 am	» Q & A	Panel
11:00 am - 2:00 pm	Exhibit Hall Open EXHIBIT HALL B	
12:30 pm - 1:30 pm	Living with Rare Neuroimmune Conditions: A Patient Panel EXHIBIT HALL B <i>Sponsored by SRNA</i>	Benjamin Greenberg, MD, Moderator

Program (Friday)



2026
ANNUAL
MEETING

2:00 pm - 5:00 pm	<p>(SYM19) Fundamentals of MS Care Part 3: Matching Treatment Decisions for the Disease Course, Co-Morbidities, Caring for Men with MS and Aging and Disability in MS: Navigating Progression</p> <p>E220AB IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB</p>	Beverly Layton, RN, BSN, MSCN, Moderator
» 2:00 pm	» Welcome and Overview	Beverly Layton, RN, BSN, MSCN
» 2:00 pm	» Matching Treatment to the Disease Course	John R. Rinker, II, MD
» 2:45 pm	» Co-Morbidities and Multiple Sclerosis	Sara Schaefer, NP-BC, CNRN, MSCN
» 3:25 pm	» Break	
» 3:40 pm	» Caring for Men with Multiple Sclerosis	Jeffrey Hernandez, DNP, APRN, MSCN
» 4:20 pm	» Aging and Disability in Multiple Sclerosis: Navigating Progression	Crystal Wright, RN, MSN, AG-PCNP-BC, MSCN
2:00 pm - 5:00 pm	<p>(SYM20) Current Topics and Trends in Rehabilitation Part 3</p> <p>Wheels for Warriors: Wheelchair Considerations for the MS Patient</p> <p>E221AB IPCE CME ANCC AOTA NCPT AAPA</p>	Patty Bobryk, MHS, PT, MSCS, ATP, Moderator Alyssa DeCarlo, MS, OTR/L, MSCS
» 2:00 pm	» Navigating the Wheelchair Process, Documentation and Insurance	
» 2:45 pm	» Complex Conversations and Manual Wheelchair Workshop	
» 3:30 pm	» Power Wheelchair and Complex rehab Technologies Workshop	
» 4:40 pm	» Case Studies, Q & A	
2:00 pm - 5:00 pm	<p>(SYM21) Managing Non-Multiple Sclerosis Patients in a Multiple Sclerosis Practice: Rare Neuroimmunological Disorders – Everything You Need to Know Part 3</p> <p>E216ABCD IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB</p>	Benjamin Greenberg, MD, Chair
» 2:00 pm	» Access to Care	Olivia Beacham, BSN, RN
» 2:40 pm	» Safety Monitoring and Vaccination Strategies	Paula Hardeman, DMSc, MPAS, PA-C
» 3:20 pm	» Break	
» 3:30 pm	» Recommendations about Pregnancy and Breast Feeding	Dalia Rotstein, MD
» 4:10 pm	» Physical Therapy Considerations for NMO, MOGAD, Sarcoid and SPS	Nora Fritz, PhD, DPT, NCS
» 4:50 pm	» Closing Comments and Adjournment	Benjamin Greenberg, MD
2:00 pm - 5:00 pm	<p>(SYM22) Advances in CSF Biomarkers for Multiple Sclerosis</p> <p>E217 IPCE CME ACPE ANCC AAPA</p>	Sharmilee Gnanapavan, MD, PhD, Chair
» 2:00 pm	» Introduction	Sharmilee Gnanapavan, MD, PhD
» 2:15 pm	» CSF OCB vs KFLC	Raphael Schneider, MD, PhD, FRCPC, CIP
» 3:00 pm	» Break	
» 3:15 pm	» Role of CSF Diagnostics in RIS	Enric Monreal, MD, PhD
» 4:00 pm	» CSF Biomarkers and Disease Progression	Simon Thebault, MBChB, MSc, PhD, MRCP(UK), FRCPC
» 4:45 pm	» Q & A	Panel

2:00 pm - 5:00 pm 	(SYM23) McDonald Criteria Part 2 – How to Use and How to Not Misuse the 2024 McDonald Criteria E219A IPCE CME ACPE ANCC AAPA	David K.B. Li, MD FRCP, Co-Chair Wallace Brownlee, MD, PhD, FRACP, Co-Chair
» 2:00 pm	» Welcome and Introductions	David K.B. Li, MD FRCP Wallace Brownlee, MD, PhD, FRACP
» 2:05 pm	» Applying the McDonald Criteria in People with Typical MS Presentations	Wallace Brownlee, MD, PhD, FRACP
» 2:35 pm	» Applying the McDonald Criteria in People with Non-specific Symptoms and RIS (Radiologically Isolated Syndrome)	Burcu Zeydan, MD
» 3:05 pm	» Applying the McDonald Criteria in Special Patient Populations	Le H. Hua, MD
» 3:25 pm	» Break	
» 3:40 pm	» Green and Red Flag MS Lesions	David K.B. Li, MD, FRCP
» 4:00 pm	» Challenges in Applying the McDonald Criteria-Misdiagnosis, Overlapping Syndromes and Global Applicability	Suma Shah, MD
» 4:30 pm	» Case Discussion and Q & A	Panel
2:00 pm - 5:00 pm	(SYM24) MS in Underserved Populations: Understanding Needs and Improving Outcomes E219BC IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Jaqueline Rosenthal, MD, Chair
» 2:00 pm	» Welcome, Session Overview, and Framing Social Determinants in MS	Jaqueline Rosenthal, MD
» 2:20 pm	» Social Determinants and MS Diagnosis & Disease Course	Annette Howard, MD
» 2:50 pm	» Infusion Centers at the Front Line: Real-World Barriers and Patient Support	Carol Coleman
» 3:20 pm	» Research, Data Gaps, and System-Level Solutions in MS Care	Mima Akinsanya, MD
» 3:50 pm	» Break	
» 4:05 pm	» The Patient Voice: Living With MS Beyond the Clinic Walls	Nana Opong-Owusu, MPH
» 4:35 pm	» Panel Discussion, Q&A, and Closing Remarks	Panel
2:00 pm - 5:00 pm	(SYM25) Spinal Cord Variants: Special Considerations in MS Diagnosis and Treatment E219D IPCE CME ANCC AAPA	Christopher C. Hemond, MD
» 2:00 pm	» Introduction and Overview-Blood-Spinal Cord Barrier: Gatekeeper or Sieve?	Christopher C. Hemond, MD
» 2:30 pm	» Myelocortical-Variant Multiple Sclerosis	Bruce D. Trapp, MD
» 3:15 pm	» Break	
» 3:30 pm	» Critical Demyelinating Lesions and Solitary Sclerosis	B. Mark Keegan, MD
» 4:10 pm	» “Spondylodemyelination”: A Convergence of Risk	Daniel Gratch, MD
» 4:40 pm	» Q&A	Panel
2:00 pm - 5:00 pm	(SYM26) Whitaker Platform Session E212ABCD IPCE CME ACPE ANCC AOTA NCPT AAPA APA RD ASWB	Ahmed Obeidat, MD, PhD, Chair
» 2:00 pm	» Introduction	Ahmed Obeidat, MD, PhD
» 2:10 pm	» (WH101) Accelerated Brain Aging Identifies Functional Deficits Not Captured By Chronological Age In Multiple Sclerosis	Patrick G. Monaghan, PhD
» 2:35 pm	» (WH102) Proteomic Age Is Accelerated In Multiple Sclerosis and Evident at the Pre-Symptomatic Stage	Fatemeh Siavoshi, MD

» 3:00 pm	» (WHI03) MIF Nuclease Inhibition Protects Neurons from Parthanatos Cell Death Following Inflammation	Sachin Gadani, MD, PhD
» 3:25 pm	» Break	
» 3:40 pm	» (WHI04) Tobacco Smoking Disrupts Bile Acid and Tryptophan Metabolism In Multiple Sclerosis	Federico Montini, MD, PhD
» 4:05 pm	» (WHI05) Clinical Measures of Ambulatory Balance Do Not Improve Prediction of Self-Reported Falls for People with Multiple Sclerosis	Mitchell D. Adam, PT, DPT
» 4:30 pm	» (WHI06) Dysregulated Tetrahydrobiopterin Pathways Impairs Oligodendrocyte Differentiation and Remyelination In Multiple Sclerosis	Zaenab Dhari, MD
» 4:55 pm	» Closing Remark	Ahmed Obeidat, MD, PhD
2:00 pm - 5:00 pm	(SYM27) Cognitive Impairment in MS: Clinical Diagnosis, Monitoring, and Rehabilitation E220CD IPCE CME ACPE ANCC AOTA AAPA APA ASWB	
	» Part 1: Providing Cognitive Rehabilitation in Clinical Practice: Can This be Done?	John DeLuca, PhD, ABPP, Chair
» 2:00 pm	▶ Introduction	John DeLuca, PhD, ABPP
» 2:05 pm	▶ Treating MS Patients with Cognitive Rehabilitation: The Time Has Come	Yael Goverover, OTR/L, PhD, FAOTA, FACRM
» 2:35 pm	▶ Can Exercise be Used to Treat Cognitive Impairment? The Evidence	Brian Sandroff, PhD
» 3:05 pm	▶ Can Treatment for Cognitive Dysfunction Become Standard of Care?*	Krupa Pandey, MD
» 3:20 pm	▶ Q & A	Panel
» 3:30 pm	» Break	
» 3:45 pm	» Part 2: The IMSCOGS-ECTRIMS Consensus Criteria to Diagnose and Monitor Cognitive Impairment in MS: Focus on the 2024 McDonald Criteria	Menno M. Schoonheim, PhD, Chair
» 3:45 pm	▶ Introduction	Menno M. Schoonheim, PhD
» 3:50 pm	▶ Diagnosing and Monitoring Cognitive Impairment in MS: IM-SCOGS-ECTRIMS Consensus Criteria	Laura Hancock, PhD, ABPP
» 4:20 pm	▶ Cognition and MRI Through the Lens of the 2024 McDonald Criteria: IMSCOGS-ECTRIMS Consensus Criteria	Menno M. Schoonheim, PhD
» 4:50 pm	▶ Summary and Q & A	Panel
5:15 pm - 6:45 pm	Closing Ceremony and Awards RICHARDSON BALLROOM	